CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).
  
  OVERVIEW OF ACTIVITY
  Lung cancer is a devastating disease with broad-reaching effects on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In the year 2018, it is estimated that approximately 234,030 individuals will be diagnosed and 154,050 will die from the disease. Despite many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, hope is renewed that these patterns have started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians. Over the past several years, major clinical trials in NSCLC have recorded a host of promising successes, many of which are already being applied in clinical practice. Even so, these achievements will doubtless continue to be dissected in the upcoming years and will further challenge the collective understanding of the biology and optimal management of this disease.
  
  This CME program was developed from the proceedings of a satellite symposium held during the 2018 ASCO Annual Meeting. It explores the most significant therapeutic advances in the field of NSCLC by using the perspectives of leading lung cancer experts on challenging cases and questions submitted by community oncologists to frame a discussion of how this information has aided in the refinement of current clinical practice and ongoing research. This activity will help medical oncologists and other allied healthcare professionals to find answers to the individualized questions and concerns they frequently encounter and to in turn provide high-quality cancer care.
  
  LEARNING OBJECTIVES

  • Use patient and disease variables in addition to published research data to guide the selection of therapy for patients with EGFR, ALK, ROS1 and BRAF mutation-positive NSCLC.
  • Recall available Phase III data documenting the benefit of sequential anti-PD-L1 therapy after completion of chemoradiation therapy for patients with Stage III NSCLC, and consider the role of durvalumab for appropriate patients.
  • Appreciate the recent FDA approval of osimertinib as first-line therapy for patients with EGFR mutation-positive NSCLC, and integrate osimertinib into the clinical management of this disease.
  • Appraise emerging research data evaluating anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic approaches for patients with metastatic NSCLC.
  • Educate patients about the side effects associated with immune checkpoint inhibitors, and provide preventive strategies to reduce or ameliorate these toxicities.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Matthew D Hellmann, MD
  Medical Oncologist
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Janssen Biotech Inc, Merck, Novartis.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Vice Chair, Radiation Therapy Oncology Group
  Philadelphia, Pennsylvania
  
  Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Ariad Pharmaceuticals Inc, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc.
  
  Geoffrey R Oxnard, MD
  Lowe Center for Thoracic Oncology
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, DropWorks CEI, GRAIL Inc, Guardant Health Inc, Ignyta Inc, Inivata, Loxo Oncology Inc.
  
  Martin Reck, MD, PhD
  Head of Department of Thoracic Oncology
  Head of Clinical Trial Department
  LungenClinic Grosshansdorf
  Grosshansdorf, Germany
  
  Consulting Agreements and Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc.
  
  Alice Shaw, MD, PhD
  Professor of Medicine
  Harvard Medical School
  Center for Thoracic Cancers
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: Blueprint Medicines; Consulting Agreements: Ariad Pharmaceuticals Inc, Blueprint Medicines, Daiichi Sankyo Inc, EMD Serono Inc, Foundation Medicine, Genentech, Ignyta Inc, KSQ Therapeutics, Loxo Oncology Inc, Natera Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Foundation Medicine, Genentech, Merck and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: July 2018
  Expiration date: July 2019